Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...
AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...
MarketBeat on MSN
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...
Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...
CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its ...
VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results